Top Markets
Coin of the day
Mural Oncology plc Mural Oncology plc

Mural Oncology plc

MURA
Rang in aandelen #27064
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Aandeelprijs
$2.04
Laatst gesynchroniseerd: 2025-12-09
Marktkapitalisatie
$35.38M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-2.39%
Land
IE
Handel Mural Oncology plc (MURA)

Categorie

Dividendrendementgeschiedenis voor Mural Oncology plc (MURA)
Het dividendrendement (TTM) van Mural Oncology plc (aandelsymbool: MURA) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Mural Oncology plc (MURA) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH